Best Peptides, Stem Cells, Testosterone & Exercise Hacks - Biohacking Roundtable - #1148

What It Covers

A biohacking roundtable featuring Ben Greenfield, Gabriel Lyon, and Brigham Buhler covers peptide protocols, MUSE stem cell therapy, GLP-1 microdosing, testosterone stigma, hydrogen therapy, and the FDA's recent hearing on peptide compounding access. The conversation spans experimental interventions, sarcopenia risks, and medical freedom debates across 170 minutes.

Key Questions Answered

• •Peptide Protocol Hierarchy: Treat peptides as condition-specific tools rather than daily supplements. Thymosin alpha-1 addresses immune support during travel, BPC-157 and TB-500 target injury recovery, and tesamorelin combined with ipamorelin and CJC-1295 runs as a twice-yearly growth hormone cycle. IGF-LR3 offers growth hormone benefits without suppressing natural production or triggering the cortisol and elevated resting glucose side effects associated with pure HGH use.
• •MUSE Stem Cells: A subset of stem cells called MUSE (multilineage stress enduring), discovered by scientist Mari Dozawa, demonstrates a 30% engraftment rate versus 3% for traditional MSCs, engrafts within 48 hours, pierces the blood-brain barrier, and survives days at room temperature. Sourced from planned C-section afterbirth, they consume damaged cells and adopt healthy phenotypes. A Japanese trial showed 90% of encephalitis-affected infants had normal brain function two years after a single intravenous treatment.
• •GLP-1 Microdosing for Inflammation: Doses as low as 0.25mg of GLP-1 agonists suppress food noise and reduce systemic inflammation without the muscle-loss risks associated with higher clinical doses. Emerging research, including insights from the scientist who discovered GLP-1's appetite effects, suggests low-dose GLP-1 may reduce cancer risk through inflammation reduction. Over 70,000 patients at one clinic report measurable inflammation improvements at microdose levels not covered by insurance.
• •Sarcopenia as the Next Epidemic: GLP-1 adoption at scale risks trading an obesity crisis for a sarcopenia crisis. Muscle loss on GLP-1s is largely driven not by the drug's mechanism but by insufficient protein intake and inability to train effectively due to low energy from reduced food volume. Maintaining lean muscle mass and bone mineral density is a leading predictor of health span. Resistance training combined with adequate protein intake must accompany any GLP-1 protocol.
• •Cold Plunge Timing and Anabolic Blunting: Post-workout cold plunges only blunt the anabolic response when muscle temperature drops by approximately one degree Celsius, requiring at least ten minutes at genuinely cold temperatures. Brief cold showers or short plunges immediately after training do not reach this threshold. Waiting several hours post-workout before a cold plunge avoids the anabolic blunting effect. Hydrogen and methylene blue function as selective antioxidants safe for post-exercise use without suppressing the hormetic training response.
• •Testosterone as the Single Most Predictive Biomarker: Total testosterone reflects risk for type 2 diabetes, depression, osteoporosis, and cardiovascular disease more reliably than any other single biomarker. The US clinical threshold of 300 ng/dL is considered too low by practitioners, and CAG repeat receptor variations mean a reading of 600 ng/dL can produce symptoms identical to hypogonadism in some individuals. Screening warfighters and other high-demand populations for low testosterone before deployment represents an unaddressed performance and health gap.
• •FDA Peptide Hearing Outcome: After submitting over 5,000 pages of documents and a retrospective analysis of 16 million BPC-157 users identifying only three adverse events, a panel of practicing clinicians voted to reinstate six of seven restricted peptides. The FDA panel voted against reinstatement along strict institutional lines. The core legal argument centers on compounding pharmacy rights established by a 1997 Congressional act, and the financial pressure from pharmaceutical companies unable to patent naturally occurring peptides drives much of the regulatory resistance.